Workflow
Weighted Average Cost of Capital (WACC)
icon
Search documents
Xponential Fitness, Inc. (NYSE:XPOF) Financial Analysis
Financial Modeling Prep· 2026-03-01 02:00
Xponential Fitness has a ROIC of 6.61% and a WACC of 28.18%, indicating inefficiencies in capital utilization.F45 Training Holdings Inc. and Treace Medical Concepts, Inc. show significant financial challenges with negative ROIC values.Sovos Brands, Inc. stands out with a ROIC of 5.54% and a WACC of 5.21%, showcasing efficient capital utilization.Xponential Fitness, Inc. (NYSE:XPOF) is a leading global franchisor of boutique fitness brands. The company offers a variety of fitness experiences through its dive ...
Collegium Pharmaceutical's Efficient Capital Utilization Stands Out in the Pharmaceutical Industry
Financial Modeling Prep· 2026-02-27 17:00
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) showcases a Return on Invested Capital (ROIC) of 10.34%, significantly outperforming its Weighted Average Cost of Capital (WACC) of 5.18%.Amphastar Pharmaceuticals and Syndax Pharmaceuticals demonstrate lower efficiency in capital utilization compared to Collegium, with Amphastar barely generating returns above its cost of capital.Ironwood Pharmaceuticals exhibits the highest efficiency with a ROIC of 62.21% and a WACC of 6.21%, indicating exceptional capital man ...
Immunocore Holdings plc (NASDAQ:IMCR) Financial Analysis
Financial Modeling Prep· 2026-02-26 17:00
Core Insights - Immunocore Holdings plc is a biotechnology company focused on developing T cell receptor-based therapeutics, currently in the development stage with high R&D costs before achieving profitability [1] - The company's Return on Invested Capital (ROIC) is -1.74%, and its Weighted Average Cost of Capital (WACC) is 7.98%, indicating it is not generating returns above its cost of capital [2][6] - The ROIC to WACC ratio for Immunocore is -0.22, which is better than some peers, suggesting a relatively better potential for capital efficiency improvement [2][6] Peer Comparison - Vor Biopharma Inc. has a ROIC of -232.79% and a WACC of 9.67%, resulting in a ROIC to WACC ratio of -24.09 [3] - Cullinan Therapeutics, Inc. reports a ROIC of -53.35% and a WACC of 4.55, leading to a ROIC to WACC ratio of -11.72 [3] - Sana Biotechnology, Inc. has a ROIC of -57.87% and a WACC of 12.06, resulting in a ROIC to WACC ratio of -4.80 [3] - Design Therapeutics, Inc. stands out with a ROIC of -38.71% and a WACC of 11.33, achieving the highest ROIC to WACC ratio of -3.42, indicating a closer potential to achieving positive returns [4] Industry Context - All companies analyzed, including Immunocore, are operating with negative ROIC, which is typical for early-stage biotechnology firms [5][6] - Investors should consider ROIC and WACC metrics alongside other factors such as pipeline progress, market potential, and financial health when evaluating investment opportunities in the biotechnology sector [5]
Shift4 Payments(FOUR) - 2025 Q4 - Earnings Call Transcript
2026-02-26 14:32
Shift4 Payments (NYSE:FOUR) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsChristopher Cruz - CFODominic Ball - VP of Equity ResearchTaylor Lauber - CEOThomas McCrohan - Head of Investor RelationsWill Nance - VPConference Call ParticipantsDan Dolev - Managing Director and Senior Fintech Equity Research AnalystDan Perlin - Managing Director and Senior Equity AnalystDarrin Peller - Managing Director and Senior AnalystTimothy Chiodo - Managing Director and Lead Equity Research AnalystO ...
Understanding Stock Yards Bancorp, Inc.'s Financial Performance in the Banking Sector
Financial Modeling Prep· 2026-02-25 17:00
Core Insights - Stock Yards Bancorp, Inc. (SYBT) operates in the competitive U.S. banking sector, providing a range of services including personal and business banking, wealth management, and investment services [1][6] Financial Performance - SYBT's Return on Invested Capital (ROIC) is 7.91%, while its Weighted Average Cost of Capital (WACC) is 13.52%, resulting in a ROIC to WACC ratio of 0.58, indicating inefficient capital utilization [2][6] - In comparison, Lakeland Financial Corporation (LKFN) has a ROIC of 10.40% and a WACC of 13.82%, leading to a ROIC to WACC ratio of 0.75, which also suggests challenges in capital efficiency [3] - Republic Bancorp, Inc. (RBCAA) shows a ROIC of 9.04% and a WACC of 8.50%, resulting in a ROIC to WACC ratio of 1.06, indicating effective capital utilization and better growth prospects compared to SYBT [4] - TriCo Bancshares (TCBK) and S&T Bancorp, Inc. (STBA) have negative ROIC to WACC ratios of -0.54 and -0.20, respectively, indicating struggles with capital efficiency [5][6]
Planet Fitness, Inc. (NYSE:PLNT) Financial Efficiency Analysis
Financial Modeling Prep· 2026-02-25 02:00
Core Insights - Planet Fitness, Inc. is a prominent fitness center operator in the U.S., known for its affordable gym memberships and "Judgement Free Zone" philosophy, which fosters an inclusive environment for all fitness levels [1] Financial Performance - Planet Fitness has a Return on Invested Capital (ROIC) of 10.12% and a Weighted Average Cost of Capital (WACC) of 9.02%, resulting in a ROIC to WACC ratio of 1.12, indicating effective capital utilization [2][6] - Compared to peers, Planet Fitness's capital efficiency is moderate, with Wingstop Inc. achieving a ROIC of 21.54% and a WACC of 10.60%, leading to a higher ROIC to WACC ratio of 2.03 [3] - Match Group, Inc. has the highest ROIC to WACC ratio of 2.42, with a ROIC of 18.50% and a WACC of 7.66%, indicating superior efficiency in generating returns relative to its cost of capital [4] - Other competitors like Five Below, Inc. and Live Nation Entertainment, Inc. have lower ROIC to WACC ratios of 0.90 and 0.99, respectively, while Dave & Buster's Entertainment, Inc. shows a negative ratio of -0.04, indicating inefficiency [5]
Arrowhead Pharmaceuticals' Capital Efficiency Outshines Among Peers
Financial Modeling Prep· 2026-02-24 02:00
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) demonstrates a strong Return on Invested Capital (ROIC) of 20.84% compared to its Weighted Average Cost of Capital (WACC) of 9.83%, indicating efficient capital utilization.ACADIA Pharmaceuticals leads with the highest ROIC to WACC ratio among peers, suggesting superior efficiency and growth potential.Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biopharmaceutical company that focuses on developing medicines that treat intractable diseases by silencing the ...
Rimini Street, Inc. (NASDAQ:RMNI) Showcases Efficient Capital Utilization
Financial Modeling Prep· 2026-02-23 02:00
Rimini Street, Inc. (NASDAQ:RMNI) is a leading provider of enterprise software support services, offering third-party support for major software brands like Oracle and SAP. This approach enables clients to significantly reduce their maintenance costs. In the competitive landscape of software support services, Rimini Street distinguishes itself through its remarkable financial performance and efficient capital utilization.Key Insights:Rimini Street's Return on Invested Capital (ROIC) is 49.18%, substantially ...
LegalZoom.com, Inc. (NASDAQ:LZ) Capital Utilization Analysis
Financial Modeling Prep· 2026-02-22 17:00
Core Insights - LegalZoom.com, Inc. provides online legal solutions for small businesses and individuals, facing competition from peers like Xometry, Cyteir Therapeutics, CS Disco, LifeStance Health Group, and Clear Secure [1] Financial Performance - LegalZoom's Return on Invested Capital (ROIC) is 6.34%, while its Weighted Average Cost of Capital (WACC) is 9.32%, resulting in a ROIC to WACC ratio of 0.68, indicating insufficient returns above its cost of capital [2] - Xometry, Inc. has a negative ROIC of -7.94% against a WACC of 7.29%, leading to a ROIC to WACC ratio of -1.09, highlighting similar challenges in capital efficiency [3] - Cyteir Therapeutics, Inc. and CS Disco, Inc. exhibit even greater inefficiencies with ROICs of -32.37% and -46.98%, respectively, and WACC figures of 5.19% and 13.20%, resulting in ROIC to WACC ratios of -6.24 and -3.56 [4] - In contrast, Clear Secure, Inc. demonstrates strong performance with a ROIC of 33.80% and a WACC of 9.10%, yielding a ROIC to WACC ratio of 3.72, indicating effective capital utilization [5][6]
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Financial Performance and Peer Comparison
Financial Modeling Prep· 2026-02-22 17:00
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has a Return on Invested Capital (ROIC) of -22.45%, indicating it is not generating sufficient returns to cover its cost of capital.Xencor, Inc. (XNCR) also has a negative ROIC but performs slightly better than Enanta in terms of its ROIC to WACC ratio.PTC Therapeutics, Inc. (PTCT) stands out with a positive ROIC of 37.39%, showcasing efficient use of capital to generate returns above its cost of capital.Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) is a biotechnology ...